Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
allo-APZ2-CVU in chronic venous ulcers
NCT04971161Phase 2Completed
- Sponsor
- RHEACELL
- Start
- Aug 2021
- Primary completion
- Nov 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EBESANAR in venous leg ulcer (VLU) (4 arms), sponsored by RHEACELL. Primary endpoints: Complete wound closure at Week 18 persisting for at least two weeks and Adverse Events at 10 months. Started Aug 2021; status: completed.
02
Drugs
EBESANAR
03
Conditions
venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT04971161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971161.